TY - JOUR
T1 - Oral Mucositis Is Associated with Distinctive Patterns of Oral Microbiota Injury in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
AU - Shouval, Roni
AU - Eshel, Adi
AU - Danylesko, Ivetta
AU - Dubovski, Bar
AU - Fein, Joshua A.
AU - Fried, Shalev
AU - Geva, Mika
AU - Kouniavsky, Elizaveta
AU - Kuperman, Amir A.
AU - Louzoun, Yoram
AU - Koren, Omry
AU - Nagler, Arnon
PY - 2019/11/1
Y1 - 2019/11/1
N2 - RS and AE, and OK and AN, had an equal contributionBackground: Oral mucositis (OM) is a debilitating complication of allogeneic hematopoietic stem cell transplantation (HSCT) propagated by an inflammatory response. While certain patient and transplantation-related characteristics increase the risk of OM, there is marked variability in OM severity across recipients even of the same treatments. Given the substantial perturbation of the gut microbiome following transplantation and its role in facilitating immune and metabolic functions, we hypothesized that the oral microbiome is also disturbed during transplantation and may explain population variation in OM severity.Methods: In this single-center observational study, we prospectively collected weakly saliva samples from adult patients undergoing allogeneic HSCT and 20 healthy control volunteers. A total of 625 saliva specimens were collected starting from 7 days before HSCT to 34 days post-transplant. Patients gave a median of 4 samples (range 1-7). Samples underwent 16S rRNA gene sequencing (V4 region) on the Illumina platform. Pre-transplantation samples were defined as those collected between days -7 and -1. Sixty pre- and post-HSCT samples underwent mass spectrometry-based metabolomic profiling (Metabolon, Durham, NC).For all patients, OM was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0, with grade 3-4 defined as severe mucositis.Results: In this largest analysis of the oral microbiome in transplant recipients, 184 patients were included. Transplantation indications varied, the leading being AML (47%). Myeloablative conditioning regimens were used in 70% of patients. Methotrexate (MTX) was given as graft-versus-host disease prophylaxis in 74% of patients. Median time to OM development was 7 days (IQR 5-9); 58% and 43% of patients developed grade 2-4 and grade 3-4 OM, respectively.Pre-transplantation oral α-diversity, as measured by the Shannon Index, was similar to that of healthy controls (p=0.460), but later decreased, reaching a trough on day 12 followed by an increase to levels that were lower than baseline at day 34 (Fig. 1A). Indeed, there was a 24% reduction in peri-engraftment α-diversity relative to pre-transplant (p
AB - RS and AE, and OK and AN, had an equal contributionBackground: Oral mucositis (OM) is a debilitating complication of allogeneic hematopoietic stem cell transplantation (HSCT) propagated by an inflammatory response. While certain patient and transplantation-related characteristics increase the risk of OM, there is marked variability in OM severity across recipients even of the same treatments. Given the substantial perturbation of the gut microbiome following transplantation and its role in facilitating immune and metabolic functions, we hypothesized that the oral microbiome is also disturbed during transplantation and may explain population variation in OM severity.Methods: In this single-center observational study, we prospectively collected weakly saliva samples from adult patients undergoing allogeneic HSCT and 20 healthy control volunteers. A total of 625 saliva specimens were collected starting from 7 days before HSCT to 34 days post-transplant. Patients gave a median of 4 samples (range 1-7). Samples underwent 16S rRNA gene sequencing (V4 region) on the Illumina platform. Pre-transplantation samples were defined as those collected between days -7 and -1. Sixty pre- and post-HSCT samples underwent mass spectrometry-based metabolomic profiling (Metabolon, Durham, NC).For all patients, OM was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0, with grade 3-4 defined as severe mucositis.Results: In this largest analysis of the oral microbiome in transplant recipients, 184 patients were included. Transplantation indications varied, the leading being AML (47%). Myeloablative conditioning regimens were used in 70% of patients. Methotrexate (MTX) was given as graft-versus-host disease prophylaxis in 74% of patients. Median time to OM development was 7 days (IQR 5-9); 58% and 43% of patients developed grade 2-4 and grade 3-4 OM, respectively.Pre-transplantation oral α-diversity, as measured by the Shannon Index, was similar to that of healthy controls (p=0.460), but later decreased, reaching a trough on day 12 followed by an increase to levels that were lower than baseline at day 34 (Fig. 1A). Indeed, there was a 24% reduction in peri-engraftment α-diversity relative to pre-transplant (p
U2 - 10.1182/blood-2019-125433
DO - 10.1182/blood-2019-125433
M3 - مقالة
SN - 0006-4971
VL - 134
SP - 3265
JO - Blood
JF - Blood
ER -